Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 91

1.

Cannabidiol as potential anticancer drug.

Massi P, Solinas M, Cinquina V, Parolaro D.

Br J Clin Pharmacol. 2013 Feb;75(2):303-12. doi: 10.1111/j.1365-2125.2012.04298.x. Review.

2.

Are cannabidiol and Δ(9) -tetrahydrocannabivarin negative modulators of the endocannabinoid system? A systematic review.

McPartland JM, Duncan M, Di Marzo V, Pertwee RG.

Br J Pharmacol. 2015 Feb;172(3):737-53. doi: 10.1111/bph.12944. Review.

3.

Local delivery of cannabinoid-loaded microparticles inhibits tumor growth in a murine xenograft model of glioblastoma multiforme.

Hernán Pérez de la Ossa D, Lorente M, Gil-Alegre ME, Torres S, García-Taboada E, Aberturas Mdel R, Molpeceres J, Velasco G, Torres-Suárez AI.

PLoS One. 2013;8(1):e54795. doi: 10.1371/journal.pone.0054795. Epub 2013 Jan 22.

4.

Cannabidiol: State of the art and new challenges for therapeutic applications.

Pisanti S, Malfitano AM, Ciaglia E, Lamberti A, Ranieri R, Cuomo G, Abate M, Faggiana G, Proto MC, Fiore D, Laezza C, Bifulco M.

Pharmacol Ther. 2017 Jul;175:133-150. doi: 10.1016/j.pharmthera.2017.02.041. Epub 2017 Feb 22. Review.

PMID:
28232276
5.

Cannabinoids Delta(9)-tetrahydrocannabinol and cannabidiol differentially inhibit the lipopolysaccharide-activated NF-kappaB and interferon-beta/STAT proinflammatory pathways in BV-2 microglial cells.

Kozela E, Pietr M, Juknat A, Rimmerman N, Levy R, Vogel Z.

J Biol Chem. 2010 Jan 15;285(3):1616-26. doi: 10.1074/jbc.M109.069294. Epub 2009 Nov 12.

6.

In vitro and in vivo efficacy of non-psychoactive cannabidiol in neuroblastoma.

Fisher T, Golan H, Schiby G, PriChen S, Smoum R, Moshe I, Peshes-Yaloz N, Castiel A, Waldman D, Gallily R, Mechoulam R, Toren A.

Curr Oncol. 2016 Mar;23(2):S15-22. doi: 10.3747/co.23.2893. Epub 2016 Mar 16.

7.

Phyto-, endo- and synthetic cannabinoids: promising chemotherapeutic agents in the treatment of breast and prostate carcinomas.

Fraguas-Sánchez AI, Fernández-Carballido A, Torres-Suárez AI.

Expert Opin Investig Drugs. 2016 Nov;25(11):1311-1323. Epub 2016 Sep 28. Review.

PMID:
27633508
8.

Cannabidiol inhibits angiogenesis by multiple mechanisms.

Solinas M, Massi P, Cantelmo AR, Cattaneo MG, Cammarota R, Bartolini D, Cinquina V, Valenti M, Vicentini LM, Noonan DM, Albini A, Parolaro D.

Br J Pharmacol. 2012 Nov;167(6):1218-31. doi: 10.1111/j.1476-5381.2012.02050.x.

9.

A tale of two cannabinoids: the therapeutic rationale for combining tetrahydrocannabinol and cannabidiol.

Russo E, Guy GW.

Med Hypotheses. 2006;66(2):234-46. Epub 2005 Oct 4.

PMID:
16209908
10.

Synthesis and pharmacological evaluation of amino, azido, and nitrogen mustard analogues of 10-substituted cannabidiol and 11- or 12-substituted delta 8-tetrahydrocannabinol.

Compton DR, Little PJ, Martin BR, Gilman JW, Saha JK, Jorapur VS, Sard HP, Razdan RK.

J Med Chem. 1990 May;33(5):1437-43.

PMID:
2158563
11.

Delta(9) -tetrahydrocannabinol and cannabidiol as potential curative agents for cancer: A critical examination of the preclinical literature.

Fowler CJ.

Clin Pharmacol Ther. 2015 Jun;97(6):587-96. doi: 10.1002/cpt.84. Epub 2015 May 2. Review.

PMID:
25669486
12.
13.

Targeting multiple cannabinoid anti-tumour pathways with a resorcinol derivative leads to inhibition of advanced stages of breast cancer.

Murase R, Kawamura R, Singer E, Pakdel A, Sarma P, Judkins J, Elwakeel E, Dayal S, Martinez-Martinez E, Amere M, Gujjar R, Mahadevan A, Desprez PY, McAllister SD.

Br J Pharmacol. 2014 Oct;171(19):4464-77. doi: 10.1111/bph.12803. Epub 2014 Sep 5.

14.

Therapeutic Potential of Non-Psychotropic Cannabidiol in Ischemic Stroke.

Hayakawa K, Mishima K, Fujiwara M.

Pharmaceuticals (Basel). 2010 Jul 8;3(7):2197-2212. Review.

15.

Inhibition of recombinant human T-type calcium channels by Delta9-tetrahydrocannabinol and cannabidiol.

Ross HR, Napier I, Connor M.

J Biol Chem. 2008 Jun 6;283(23):16124-34. doi: 10.1074/jbc.M707104200. Epub 2008 Apr 7.

16.

Effects of cannabinoids Δ(9)-tetrahydrocannabinol, Δ(9)-tetrahydrocannabinolic acid and cannabidiol in MPP+ affected murine mesencephalic cultures.

Moldzio R, Pacher T, Krewenka C, Kranner B, Novak J, Duvigneau JC, Rausch WD.

Phytomedicine. 2012 Jun 15;19(8-9):819-24. doi: 10.1016/j.phymed.2012.04.002. Epub 2012 May 7.

PMID:
22571976
17.

Non-psychoactive cannabinoids modulate the descending pathway of antinociception in anaesthetized rats through several mechanisms of action.

Maione S, Piscitelli F, Gatta L, Vita D, De Petrocellis L, Palazzo E, de Novellis V, Di Marzo V.

Br J Pharmacol. 2011 Feb;162(3):584-96. doi: 10.1111/j.1476-5381.2010.01063.x.

18.

The effects of cannabidiol and tetrahydrocannabinol on motion-induced emesis in Suncus murinus.

Cluny NL, Naylor RJ, Whittle BA, Javid FA.

Basic Clin Pharmacol Toxicol. 2008 Aug;103(2):150-6. doi: 10.1111/j.1742-7843.2008.00253.x.

19.

Differential effects of THC- or CBD-rich cannabis extracts on working memory in rats.

Fadda P, Robinson L, Fratta W, Pertwee RG, Riedel G.

Neuropharmacology. 2004 Dec;47(8):1170-9.

PMID:
15567426
20.

Current Status and Prospects for Cannabidiol Preparations as New Therapeutic Agents.

Fasinu PS, Phillips S, ElSohly MA, Walker LA.

Pharmacotherapy. 2016 Jul;36(7):781-96. doi: 10.1002/phar.1780. Review.

PMID:
27285147

Supplemental Content

Support Center